{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:20:28Z","timestamp":1790907628158,"version":"4.1.0"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2009,3,25]],"date-time":"2009-03-25T00:00:00Z","timestamp":1237939200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>HIV-associated lipoatrophy has been associated with mitochondrial dysfunction induced by nucleoside reverse transcriptase inhibitor therapy. We hypothesize that lipid profiles and markers of mitochondrial function will improve in HIV-lipoatrophic patients switched to the nucleotide analogue tenofovir.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ten patients receiving stavudine, lamivudine and lopinavir\/ritonavir (Kaletra\u00ae) for over 6 years were switched from stavudine to tenofovir for 48 weeks. Subcutaneous fat tissue biopsies, fasting metabolic tests, HIV RNA, CD4 cell count and whole body dual energy X-ray absorptiometry (DEXA) scans were obtained at study entry and week 48. Mitochondrial DNA (mtDNA) copies\/cell and mitochondrial morphology were assessed in adipose tissue biopsies, mtDNA 8-oxo-deoxyguanine in peripheral blood mononuclear cells, and glutathione (GSH) and F2-isoprostane in plasma.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>There was no change in limb fat mass by DEXA; however, trunk fat mass increased by 18.9% (P = 0.01). Fasting total cholesterol decreased by 33 mg\/dL (P = 0.005) and serum glucose decreased by 4 mg\/dL (P = 0.039). mtDNA copies\/cell increased from 386 to 1537 (P &amp;lt; 0.001). Transmission electron microscopy showed that mitochondrial cristae were lacking or poorly defined at study entry, whereas mitochondrial inner structures were more well defined and outer membranes were intact at 48 weeks. Oxidative damage decreased in 8\/10 patients, GSH increased and F2-isoprostane decreased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The results from this study demonstrate that systemic and peripheral fat mitochondria improve in patients switched to tenofovir following long-term exposure to stavudine, while continuing protease inhibitor therapy.<\/jats:p><\/jats:sec>","DOI":"10.1093\/jac\/dkp100","type":"journal-article","created":{"date-parts":[[2009,3,26]],"date-time":"2009-03-26T00:34:16Z","timestamp":1238027656000},"page":"1244-1250","source":"Crossref","is-referenced-by-count":40,"title":["Mitochondrial function, morphology and metabolic parameters improve after switching from stavudine to a tenofovir-containing regimen"],"prefix":"10.1093","volume":"63","author":[{"given":"Mariana","family":"Gerschenson","sequence":"first","affiliation":[{"name":"\u00a0Hawaii AIDS Clinical Research Program, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Kim","sequence":"additional","affiliation":[{"name":"\u00a0Hawaii AIDS Clinical Research Program, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baiba","family":"Berzins","sequence":"additional","affiliation":[{"name":"\u00a0Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Babafemi","family":"Taiwo","sequence":"additional","affiliation":[{"name":"\u00a0Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Libutti","sequence":"additional","affiliation":[{"name":"\u00a0Hawaii AIDS Clinical Research Program, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Choi","sequence":"additional","affiliation":[{"name":"\u00a0Hawaii AIDS Clinical Research Program, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana","family":"Chen","sequence":"additional","affiliation":[{"name":"\u00a0Hawaii AIDS Clinical Research Program, Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI 96816, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Weinstein","sequence":"additional","affiliation":[{"name":"\u00a0Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Shore","sequence":"additional","affiliation":[{"name":"\u00a0Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"da Silva","sequence":"additional","affiliation":[{"name":"\u00a0Abbott Laboratories, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Belsey","sequence":"additional","affiliation":[{"name":"\u00a0Sigma Clinical, Chicago, IL, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grace A.","family":"McComsey","sequence":"additional","affiliation":[{"name":"\u00a0Case Western Reserve University, Pediatric Infectious Diseases and Rheumatology, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Murphy","sequence":"additional","affiliation":[{"name":"\u00a0Division of Infectious Diseases, Feinberg School of Medicine, Northwestern University Chicago, IL 60611, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2009,3,25]]},"reference":[{"key":"2021061512504449400_DKP100C1","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.mito.2004.07.025","article-title":"Mitochondrial dysfunction in AIDS and its treatment","volume":"4","author":"Gerschenson","year":"2004","journal-title":"Mitochondrion"},{"key":"2021061512504449400_DKP100C2","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJM199810293391806","article-title":"Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor","volume":"339","author":"Carr","year":"1998","journal-title":"N Engl J Med"},{"key":"2021061512504449400_DKP100C3","doi-asserted-by":"crossref","first-page":"F51","DOI":"10.1097\/00002030-199807000-00003","article-title":"A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors","volume":"12","author":"Carr","year":"1998","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C4","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00002030-199904160-00020","article-title":"Lipodystrophy in patients naive to HIV protease inhibitors","volume":"13","author":"Madge","year":"1999","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C5","doi-asserted-by":"crossref","first-page":"F25","DOI":"10.1097\/00002030-200002180-00001","article-title":"A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution to protease inhibitor-related lipodystrophy syndrome","volume":"14","author":"Carr","year":"2000","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C6","first-page":"78","article-title":"Metabolic outcomes of ACTG 5142: a prospective, randomized, Phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection","author":"Haubrich"},{"key":"2021061512504449400_DKP100C7","first-page":"234","article-title":"A 96-week comparison of lopinavir-ritonavir combination therapy followed by lopinavir-ritonavir monotherapy versus efavirenz combination therapy","volume-title":"J Infect Dis","author":"Cameron","year":"2008"},{"key":"2021061512504449400_DKP100C8","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/em.20223","article-title":"A brief overview of mechanisms of mitochondrial toxicity from NRTIs","volume":"48","author":"Kohler","year":"2007","journal-title":"Environ Mol Mutagen"},{"key":"2021061512504449400_DKP100C9","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1097\/00002030-200109280-00009","article-title":"Mitochondrial DNA decrease in subcutaneous adipose tissue of HIV-infected individuals with peripheral lipoatrophy","volume":"15","author":"Shikuma","year":"2001","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1097\/00002030-200306130-00007","article-title":"Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy","volume":"17","author":"Nolan","year":"2003","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C11","doi-asserted-by":"crossref","first-page":"M83","DOI":"10.1177\/135965350501002S09","article-title":"Mitochondrial DNA levels of peripheral blood mononuclear cells and subcutaneous adipose tissue from thigh, fat and abdomen of HIV-1 seropositive and negative individuals","volume":"10","author":"Gerschenson","year":"2005","journal-title":"Antivir Ther"},{"key":"2021061512504449400_DKP100C12","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1097\/00002030-199909100-00009","article-title":"A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy","volume":"13","author":"Saint-Marc","year":"1999","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C13","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1097\/00002030-200304110-00021","article-title":"Replacing stavudine by abacavir reduces lactate levels and may improve lipoatrophy","volume":"17","author":"Garcia-Benayas","year":"2003","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C14","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00126334-200305010-00005","article-title":"Randomized, controlled, 48-week study of switching stavudine and\/or protease inhibitors to combivir\/abacavir to prevent or reverse lipoatrophy in HIV-infected patients","volume":"33","author":"John","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021061512504449400_DKP100C15","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1086\/380790","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study","volume":"38","author":"McComsey","year":"2004","journal-title":"Clin Infect Dis"},{"key":"2021061512504449400_DKP100C16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061512504449400_DKP100C17","first-page":"191","article-title":"Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume-title":"JAMA","author":"Gallant","year":"2004"},{"key":"2021061512504449400_DKP100C18","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.292.2.191","article-title":"Efficacy and safety of tenofovir DF vs. stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial","volume":"292","author":"Gallant","year":"2004","journal-title":"JAMA"},{"key":"2021061512504449400_DKP100C19","first-page":"54","article-title":"Metabolic and anthropometric changes one year after switching from didanosine\/stavudine to tenofovir in HIV-infected patients","volume":"12","author":"Claas","year":"2007","journal-title":"Eur J Med Res"},{"key":"2021061512504449400_DKP100C20"},{"key":"2021061512504449400_DKP100C21","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00126334-200304010-00004","article-title":"Placenta and cord blood mitochondrial DNA toxicity in HIV-infected women receiving nucleoside reverse transcriptase inhibitors during pregnancy","volume":"32","author":"Shiramizu","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021061512504449400_DKP100C22","first-page":"257","article-title":"Gene-specific and mitochondrial repair of oxidative DNA damage","volume":"113","author":"Anson","year":"1999","journal-title":"Methods Mol Biol"},{"key":"2021061512504449400_DKP100C23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1385\/1-59259-973-7:155","article-title":"Gene-specific and mitochondrial repair of oxidative DNA damage","volume":"314","author":"Anson","year":"2006","journal-title":"Methods Mol Biol"},{"key":"2021061512504449400_DKP100C24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1097\/00002030-200501030-00002","article-title":"Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine","volume":"19","author":"McComsey","year":"2005","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C25","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1128\/AAC.38.8.1824","article-title":"Comparison of mitochondrial morphology, mitochondrial DNA content, and cell viability in cultured cells treated with three anti-human immunodeficiency virus dideoxynucleosides","volume":"38","author":"Medina","year":"1994","journal-title":"Antimicrob Agents Chemother"},{"key":"2021061512504449400_DKP100C26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0026-0495(00)80077-3","article-title":"What is oxidative stress?","volume":"49","author":"Betteridge","year":"2000","journal-title":"Metabolism"},{"key":"2021061512504449400_DKP100C27","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.mito.2004.05.014","article-title":"Oxidative stress and mitochondrial DNA repair: implications for NRTIs induced DNA damage","volume":"4","author":"Hashiguchi","year":"2004","journal-title":"Mitochondrion"},{"key":"2021061512504449400_DKP100C28","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1172\/JCI1418","article-title":"AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins","volume":"102","author":"de la Asuncion","year":"1998","journal-title":"J Clin Invest"},{"key":"2021061512504449400_DKP100C29","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/hep.510290353","article-title":"Zidovudine (AZT) causes an oxidation of mitochondrial DNA in mouse liver","volume":"29","author":"de la Asuncion","year":"1999","journal-title":"Hepatology"},{"key":"2021061512504449400_DKP100C30","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1093\/carcin\/21.5.1059","article-title":"Oxidative DNA damage in fetal tissues after transplacental exposure to 3\u2032-azido-3\u2032-deoxythymidine (AZT)","volume":"21","author":"Bialkowska","year":"2000","journal-title":"Carcinogenesis"},{"key":"2021061512504449400_DKP100C31","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S0003-9861(03)00316-3","article-title":"Oxidative DNA damage induced by photodegradation products of 3(\u2032)-azido-3(\u2032)-deoxythymidine","volume":"416","author":"Iwamoto","year":"2003","journal-title":"Arch Biochem Biophys"},{"key":"2021061512504449400_DKP100C32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0005-2728(80)90141-3","article-title":"Glutathione and the mitochondrial reduction of hydroperoxides","volume":"590","author":"Jocelyn","year":"1980","journal-title":"Biochim Biophys Acta"},{"key":"2021061512504449400_DKP100C33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1096\/fasebj.13.9.1055","article-title":"Oxidative damage to mitochondrial DNA and glutathione oxidation in apoptosis: studies in vivo and in vitro","volume":"13","author":"Esteve","year":"1999","journal-title":"FASEB J"},{"key":"2021061512504449400_DKP100C34","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0006-2952(95)02072-1","article-title":"The isoprostanes. Current knowledge and directions for future research","volume":"51","author":"Morrow","year":"1996","journal-title":"Biochem Pharmacol"},{"key":"2021061512504449400_DKP100C35","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0022-3565(25)12087-9","article-title":"Immunological characterization of urinary 8-epi-prostaglandin F2 alpha excretion in man","volume":"275","author":"Wang","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"2021061512504449400_DKP100C36","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/00126334-200309010-00006","article-title":"Lipid oxidative markers are significantly increased in lipoatrophy but not in sustained asymptomatic hyperlactatemia","volume":"34","author":"McComsey","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"2021061512504449400_DKP100C37","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1097\/01.aids.0000247574.33998.03","article-title":"A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy","volume":"20","author":"Moyle","year":"2006","journal-title":"AIDS"},{"key":"2021061512504449400_DKP100C38","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose versus switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV-infected patients","volume":"12","author":"Milinkovic","year":"2007","journal-title":"Antivir Ther"},{"key":"2021061512504449400_DKP100C39","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1001\/jama.288.2.207","article-title":"Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial","volume":"288","author":"Carr","year":"2002","journal-title":"JAMA"},{"key":"2021061512504449400_DKP100C40","first-page":"263","article-title":"Increased adipocyte apoptosis in lipoatrophy improves within 48 weeks of switching patient therapy from stavudine to abacavir or zidovudine","volume":"38","author":"Cherry","year":"2005","journal-title":"J Acquir Immune Defic Syndr"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/63\/6\/1244\/38646199\/jac_63_6_1244.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/63\/6\/1244\/38646199\/jac_63_6_1244.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T17:43:16Z","timestamp":1739036596000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/63\/6\/1244\/748034"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,25]]},"references-count":40,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2009,3,25]]},"published-print":{"date-parts":[[2009,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkp100","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published-other":{"date-parts":[[2009,6]]},"published":{"date-parts":[[2009,3,25]]}}}